View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 4, 2022

Avacta advance to next dose in Phase I study of cancer asset

AVA6000 is a prodrug of the chemotherapy doxorubicin. The SDMC reviewed the safety data from the first cohort and recommended advancing the trial.

Avacta has announced the progression of dose escalation in the Phase I ALS-6000-101 clinical trial of AVA6000, a prodrug of the chemotherapy doxorubicin. 

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The latest move to progress to the next dose group comes after the Safety Data Monitoring Committee (SDMC) of the company provided a positive review.

The safety findings from the first arm administered with 80mg/m2 AVA6000 in the trial was reviewed by the SDMC, which comprises clinicians who are presently enrolling subjects. 

On concluding the evaluation, the SDMC advised that the trial can progress as scheduled, with the next dose of AVA6000 increasing to 120mg/m2.

Avacta Group CEO Dr Alastair Smith said: “We are delighted with the SDMC’s recommendation to move on to the next dose of AVA6000 in our dose-escalation study following its positive review of the safety data from patients in the first cohort.

“We are very excited by the potential of AVA6000, and the pre|CISION platform more broadly, to deliver ground-breaking and affordable cancer treatments that have the potential to significantly improve patients’ lives.”

AVA6000 is a form of doxorubicin. It is designed to boost doxorubicin’s therapeutic index and safety using the pre|CISION platform of Avacta .

In November last year, the US Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application of Avacta for AVA6000. 

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena